Sarepta Therapeutics Deaths

News

FDA Probes Death of Boy in Brazil

FDA probes death of patient on Sarepta's Elevidys, partner Roche says death unrelated to therapy

The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics' muscular disorder gene therapy Elevidys.

Bloomberg on MSN · 1d

FDA Probes Death of Boy in Brazil on Sarepta’s Elevidys

US regulators are investigating the death of an 8-year-old boy in Brazil who received Sarepta Therapeutics Inc.’s Elevidys.

Seeking Alpha on MSN · 13h

Sarepta denies Elevidys is linked to latest patient death in Brazil

Shortly after the U.S. FDA announced an investigation into the death of a patient who had received Elevidys, a gene therapy developed by Sarepta Therapeutics (NASDAQ:SRPT), the company said that the death reported in Brazil is unrelated to its treatment.

Fierce Biotech8d

UPDATED: Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Sarepta Therapeutics: Why Is SRPT Stock Crashing?

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...

Investor's Business Daily on MSN1d

Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe

Sarepta Therapeutics'SRPT brutal week continued Friday after European officials rejected the company's controversial gene therapy, Elevidys.The rejection, which was delivered to European partner ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results